Corsano Health
Continuous wearable monitoring
Corsano Health makes CardioWatch wearables and monitoring software that collect vital signs for hospital care, home monitoring, and clinical research.
Best for
- Hospitals expanding continuous monitoring beyond conventional bedside equipment
- Research teams needing wearable measurements and raw-data access
Not ideal for
- Consumers seeking a general fitness watch
- Providers expecting a wearable purchase to include a staffed monitoring service
Bottom line
Corsano Health is a useful candidate for continuous monitoring programs that can act on the measurements they collect. CardioWatch combines a wearable form factor with clinical and research data tools, while integration and the clinical response process determine its practical value.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Corsano serves hospitals, research organizations, and partners building patient-monitoring services. BioIntelliSense is a genuine alternative for continuous wearable vital-sign monitoring, although its adhesive BioButton and Corsano’s wrist-worn CardioWatch involve different patient and deployment considerations. These are medical monitoring decisions, not ordinary smartwatch purchases.
Costs include devices, connectivity, software, integration, and clinical work after a measurement arrives. A hospital comparing offers needs the same monitoring duration, measured parameters, and escalation arrangements. Research access to raw signals is another separate requirement and may change the appropriate configuration.
- Monitoring and clinical evidence (7.4): Regulatory clearances and research use support measurement applications; care outcomes still depend on the response model.
- Wearable and data platform (7.9): Multiparameter wearables, APIs, and research data access support clinical and research workflows.
- Clinical rollout and integration (6.8): Wearable deployment requires connectivity, health-record integration, and clear responsibility for alerts.
- Pricing clarity (5.9): Hardware, platform, and distribution terms are not supplied as a public rate card.
Measurements and Data Access
Corsano’s CardioWatch 287 system supports multiparameter monitoring in clinical care and research. The U.S. distribution announcement describes heart rate, intermittent respiratory rate, oxygen saturation, skin temperature, and activity. Its broader research platform offers raw and processed data, export tools, APIs, and software-development interfaces.
The distinction between a raw sensor signal, a validated measurement, and an approved clinical function matters. Corsano notes that feature availability varies with country and regulatory authorization. A buyer should specify the model, intended population, parameters, and jurisdiction, particularly when moving a research configuration into routine care.
Hospital Deployment and Distribution
The company describes health-record integration and monitoring that can continue from hospital to home. Those capabilities are useful when patients change care setting, but a deployment still needs device assignment, connection checks, workflow testing, and responsibility for reviewing changes in a patient’s condition.
Medtronic’s arrangement provides exclusive U.S. distribution of the Corsano wearable for hospital and hospital-to-home use. It is a distribution agreement, and the opened announcement does not describe an acquisition. For hospitals, that changes the purchasing and support route, while the clinical and technical assessment remains specific to the Corsano system.
Product and service details: corsano.com, corsano.com.
Company scale
HIR estimates annual revenue below $20 million from the specialist product rollout and the scale of the published team roster. Scale source
What People Say
What people like
"CardioWatch offers automated vital signs monitoring and integrates data into health records, easing our nursing staff's workload."
"As a part of the DETECT consortium, our collaboration with Corsano has been instrumental in advancing technological solutions aimed at the early detection of cardiac arrest."
What people don't like
"The device still needs a reliable connection and a team that responds to the data."
Where customer reviews couldn't be found, our analysts attempted to give a voice to buyer sentiment, drawing on real information from review sites, forums and product documentation.
Based on: Product or service details, Product or service details.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| Corsano Health | 7.2 | 6.8 |
| BioIntelliSense | 7.2 | 7.0 |
Pricing
| Item | Detail |
|---|---|
| Commercial model | Device and platform pricing requires a proposal; no standard price is published in the opened product material. |
| U.S. hospital use | The distribution announcement identifies Medtronic as the exclusive U.S. distributor for hospital and hospital-to-home use. |
| Research | Confirm raw-data access, sampling configuration, exports, and support for the study. |
| Total cost | Include integration, replacements, connectivity, training, and staff review of monitoring data. |
Leadership
Methodology
We reviewed product documentation, published service evidence, pricing, and customer accounts available on November 8, 2026. Scores are editorial assessments on a ten-point scale. The overall score weights outcomes and workflow value at 35%, product at 30%, implementation at 20%, and pricing clarity at 15%. Company-published results describe the reported service or study; they are not a forecast for every customer.
Revenue estimates are identified as estimates. Existing peer scores are carried from the linked HIR reviews.
Sources
- Healthcare Industry Reviews analysis of the product, service, and pricing sources below, conducted November 2026.
- corsano.com ·
- corsano.com · company/team
- corsano.com · company/about us
- corsano.com · medtronic expands its acute care monitoring wearables portfolio in the u s with a new distribution agreement for the corsano multi parameter wearable